Skip to main content

Xyosted News

Testosterone Tied to Incidence, Progression of Metabolic Syndrome

THURSDAY, July 11, 2024 – Testosterone is associated with a greater risk for development and progression of metabolic syndrome, particularly in transmasculine individuals, according to a study...

Male Birth Control Gel Shows Promise in Trial

MONDAY, June 3, 2024 – A new hormonal gel could one day be a potential form of birth control for men, researchers reported Sunday. “The development of a safe, highly effective and reliably r...

All-Cause Mortality Risk Up for Men With Low Testosterone

MONDAY, May 13, 2024 – The risk for all-cause mortality is increased for men with low testosterone, high luteinizing hormone, or very low estradiol, according to a review published online May 14 in...

FDA Medwatch Alert: FDA Alerts Customers to Voluntary Recall of Compounded Drugs Due to Sterility Issues by Drug Depot, LLC, dba APS Pharmacy

April 26, 2022 --FDA is alerting patients, health care professionals, veterinarians, and animal owners/caretakers about a voluntary recall by Drug Depot, LLC, doing business as APS Pharmacy, of...

FDA Approves Xyosted (testosterone enanthate) Injection for Testosterone Replacement Therapy in Adult Males

EWING, N.J., Oct. 01, 2018 (GLOBE NEWSWIRE) – Antares Pharma, Inc. (NASDAQ:ATRS) today announced the approval of Xyosted (testosterone enanthate) injection by the U.S. Food and Drug Administration...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Hypogonadism - Male

Xyosted patient information at Drugs.com